Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma.

CONCLUSIONS: This study creates a foundation for molecular understanding of and drug development for canine lung cancer. These data also establish molecular contexts for comparative studies in dogs and humans of low mutation burden, never-smoker lung cancer and mutant HER2 function and inhibition.
PMID: 31431454 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 19, 2019 Category: Cancer & Oncology Authors: Lorch G, Sivaprakasam K, Zismann VL, Perdigones N, Contente-Cuomo T, Nazareno A, Facista SJ, Wong S, Drenner K, Liang WS, Amann JM, Sinicropi-Yao SL, Koenig MJ, LaPerle K, Whitsett TG, Murtaza M, Trent JM, Carbone DP, Hendricks WPD Tags: Clin Cancer Res Source Type: research